Group items tagged

This FOA encourages research relevant to the development of therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as "high priority" genetic conditions where screening may be possible in the near future. Demonstrating the benefits of treatment is often a primary criterion for including a condition on a newborn screening panel; therefore, this FOA, a "high priority" condition is one where screening is not currently recommended but would significantly benefit from early identification and treatment. Also listed under R03

Hearing Health Foundation (HHF) is requesting research proposals that will significantly advance our understanding of disease mechanisms, or diagnosis and treatment of Ménière's Disease, the inner ear and balance disorder. Areas of interest include the mechanisms of endolymphatic hydrops including mechanisms of cochlear fluid regulation; genetics; the creation of animal models; vertigo; vestibular migraines; the imaging of hydrops; and etiology, diagnosis, and treatment.

The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus.

The National Council on Disability (NCD) is seeking proposals for a report series on bioethics and disability. The report series will examine policies and practices related to the availability of medical interventions and life-saving medical care for people with disabilities. It will examine five specific areas where disability and bioethics intersect, with a focus on how a person's disability impacts medical decisions: organ transplants; medical futility; physician assisted suicide; genetic testing for fetal disability; and Quality Adjusted Life Years. Each report will make findings and recommendations aimed at improving access to life-saving medical care for people with disabilities, and improving the understanding of policy makers and the medical community on the value of the lives of people with disabilities.

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems.

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed

Research progress in the treatment for diseases of the exocrine pancreas [chronic pancreatitis (CP), pancreatogenic diabetes mellitus, and pancreatic cancer] has been hampered by the disorders' heterogeneity, the limitations of previous small cross-sectional studies, the inability to safely obtain pancreatic tissue for discovery, and the lack of structured epidemiology tools, genetic testing, and biomarker development and validation. Mechanism-based research of these diseases has suffered from the lack of systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. Given the increasing incidence and prevalence of CP and its association to the development of pancreatic cancer, its complications, high mortality rate, and associated health care cost, the National Institute for Diabetes and Digestive and Kidney Diseases and the National Cancer Institute established in 2015 the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium as multidisciplinary teams composed of members from the Clinical Centers and Coordination and Data Management Center to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with CP (including adults and children with recurrent acute pancreatitis) to develop treatments and gain insight into the pathophysiology of CP and its sequela: chronic pain, pancreatic exocrine and endocrine insufficiency, T3cDM, and the diabetes/pancreatic cancer association. Another objective was to undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients

We encourage applications from innovators working in all aspects of pediatric oncology, pediatric surgical care, and influenza. Specific areas of focus include: Pediatric Oncology -Innovations in pediatric oncology port technologies -Drugs that target pediatric-specific driver genes -Bedside, rapid tumor genetic testing Pediatric Surgical Care -Pediatric-specific implants for trauma & fracture care including growth-enabling spine & trauma orthopedic implants -Innovative treatment options for adolescent idiopathic scoliosis -Surgical robotics to treat pediatric patients Influenza -Pediatric-focused innovations in influenza -Novel solutions for influenza vaccine delivery -Influenza pre-exposure including antivirals prophylaxis formulation Applications will be accepted across: -Pharmaceuticals -Medical devices -Consumer products -Global public health -Health technologies -Cross-sector initiatives (an integration of one or more areas of focus mentioned above) Submissions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria: -Potential impact -Uniqueness of solution & level of competition in the current market -Quality & feasibility of the technology -Team credibility & capabilities -Plans for utilizing JLABS @ Washington, DC

The over-arching goal of this NIDCD R25 program is to support educational activities that foster a better understanding of biomedical research and its implications in the areas of auditory and vestibular research. The complexity of auditory and vestibular biology processes provide our hearing and balance function. Interruption of these processes may occur from a variety of factors, including genetic, environmental and pathogenic agents, and often results in the loss of hearing and balance function. While loss or impairment of these functions are most often non-life-threatening, the disruption to quality of life is substantial. Since August of 2007, the National Institute on Deafness and Other Communication Disorders (NIDCD) (http://www.nidcd.nih.gov/) has supported a special topics course in auditory and vestibular biology. The two to three week course, Biology of the Inner Ear, has been held at the Marine Biological Laboratory in Woods Hole, MA, and has brought together outstanding faculty to provide hands-on instruction to participants. It is the continued intent of the NIDCD to foster the advancement of research methodologies and technologies to improve, hasten and implement new treatments for these disorders and impairments. It is based on this template of excellence that the NIDCD invites R25 applications for support of a special topics course in the auditory and vestibular sciences. The purpose of this five-year initiative is to support three courses to be offered each in years 2021, 2023, and 2025. This will allow for a sustained specialized topics course that provides lecture and hands-on research exposure to the auditory and vestibular sciences. The target audience envisioned for this course consists of advanced graduate students, post-doctoral fellows and established early stage research investigators.

This Funding Opportunity Announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke (NINDS) in conjunction with the NIH Pain Consortium. It solicits R21 grant applications from institutions/organizations to perform innovative research that will elucidate the mechanisms underlying migraine, expand our current knowledge of the role of genetic, physiological, biopsychosocial, and environmental influences in migraine susceptibility and progression, and explore new therapeutic targets and therapies for acute migraine management and longer term prevention. 

 This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism.  The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institute's mission.  These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan.  Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research

This initiative encourages research that targets the reduction of health disparities among children. Investing in early childhood development is essential. Specific targeted areas of research include bio-behavioral studies that incorporate multiple factors that influence child health disparities such as biological (e.g., genetics, cellular, organ systems), lifestyle factors, environmental (e.g., physical and family environments) social (e.g., peers), economic, institutional, and cultural and family influences; studies that target the specific health promotion needs of children with a known health condition and/or disability; and studies that test, evaluate, translate, and disseminate health promotion prevention and interventions conducted in traditional and non -traditional settings. Also listed under R21

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.

The purpose of this funding opportunity announcement (FOA) is to support exploratory/developmental research that explores the premise that fertility status can be a marker for overall health. It is clear that chronic conditions such as cancer, diabetes, and obesity can impair fertility, however less is known about the extent to which fertility status can impact or act as a marker for overall health. Data suggest that infertility is not necessarily a unique disease of the reproductive axis, but is often physiologically or genetically linked with other diseases and conditions. Recent epidemiologic studies demonstrate links between fertility status in both males and females and various somatic diseases and disorders. Taken together, these data strongly suggest that fertility status can be a window into overall health. This FOA focuses on studies evaluating fertility as a marker for overall health and therefore applications that look at the effects of a disease or disorder on fertility are outside the scope of this program.

The Ohio Affiliate of  Prevent Blindness is accepting applications for its 2018 Young Investigator Student Fellowship Awards for Female Scholars in Vision Research. The Fellowship Program is designed to provide support for outstanding female scientists committed to pursuing biomedical, behavioral or clinical research careers relevant to the mission of Prevent Blindness - to prevent blindness and preserve sight.  Grants will be awarded for the summer 2018 session.  Awards will range from $3000-$5000 depending upon the availability of funds. The deadline for receipt of applications is Feb. 15, 2018. Applicants must be post-baccalaureate students enrolled in a master's or doctorate program during the summer of 2018, female, citizens or permanent residents of the United States, and conducting their research with a recognized academic institution in the State of Ohio. Applications from diverse fields in the health sciences including, but not limited to ophthalmology, optometry, nursing, genetics, public health, nutrition, gerontology, and bioengineering, are appropriate to the goals of this fellowship award. The Ohio Affiliate of Prevent Blindness encourages fellowship applications which investigate public health issues related to the burden of eye-related health and safety topics.

The purpose of this FOA is to announce support for meritorious research projects that address research questions relevant to human dental, oral, or craniofacial (DOC) conditions or traits through analysis of existing and publicly available genomics data using statistical and computational approaches. Data analysis for each project can be performed using existing and/or novel methods to be developed in the same project, including machine learning-based methods (ML). In addition to analysis of existing data, experimental or in silico work is required to validate data analysis results, or to validate a newly developed analytic method. Work that tackles causal mechanisms of action for onset and progression of disease for identified candidate causal genetic variants is highly encouraged.

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes that occurs during or after one or more episodes of acute pancreatitis. The teams will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have impaired glucose tolerance or diabetes mellitus after one or more episodes of acute pancreatitis due to various identifiable etiologies. Applications for the Data Coordinating Center (DCC) are submitted in response to a separate FOA: RFA-DK-19-023: Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center (T1DAPC-DCC) (U01).

This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after acute pancreatitis.. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.

The Children's Heart Foundation's 2020 Call for Research Proposals is now open! The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques including, but not limited to the following areas:  Genetics Biochemistry Pharmacology Devices and procedural research (cardiac catheterization and surgery) Neurodevelopmental and functional outcomes Quality and policy regarding delivery of care, coverage, and access Maternal environment and modifiable disease impact on fetuses with CHD Fetal diagnosis and intervention Long-term care of adults with CHDs Technological development and advancements